1. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials

   • Sarah Cargnin
   • Jae Il Shin
   • Salvatore Terrazzino

   Review Article 01 October 2020 Pages: 577 - 588

   

2. A preliminary assessment of oral monepantel’s tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors

   • Anna Mislang
   • Richard Mollard
   • Michael P. Brown

   Original Article 22 September 2020 Pages: 589 - 594

   

3. Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial

   • Hong Xiang
   • Lucy Liu
   • Helen Collins

   Original Article Open access 23 September 2020 Pages: 595 - 606

   

4. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy

   • Masahito Kotaka
   • Yoji Saito
   • Ichinosuke Hyodo

   Original Article Open access 23 September 2020 Pages: 607 - 618

   

5. Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia

   • Chandra Prakash
   • Bin Fan
   • Hua Yang

   Original Article 25 September 2020 Pages: 619 - 632

   

6. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine

   • Anand Joshi
   • Brian F. Kiesel
   • Jan H. Beumer

   Original Article 28 September 2020 Pages: 633 - 640

   

7. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

   • Yoriko Yamashita-Kashima
   • Sei Shu
   • Yasushi Yoshimura

   Original Article Open access 30 September 2020 Pages: 641 - 654

   

8. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system

   • Qianqian Fan
   • Jie Ma
   • Bin Zhao

   Original Article 01 October 2020 Pages: 655 - 662

   

9. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1

   • Jinghua Huang
   • Changxiu Lin
   • Dongchun Jin

   Original Article 08 October 2020 Pages: 663 - 672

   

10. Efficacy and safety of oral magnesium supplementation in reducing febrile neutropenia episodes in children with solid tumors treated with cisplatin-based chemotherapy: randomized clinical trial

    • Osvaldo D. Castelán-Martínez
    • Miguel A. Palomo-Colli
    • Martha A. Sánchez-Rodríguez

    Original Article 08 October 2020 Pages: 673 - 679

    

11. Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion

    • Heitor Pinhata Cecilio
    • Vitor Bonetti Valente
    • Daniel Galera Bernabé

    Short Communication 27 September 2020 Pages: 681 - 686

    

12. Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples

    • Chadi Abbara
    • Guillaume Drevin
    • Marie Briet

    Short Communication 29 September 2020 Pages: 687 - 691

    

13. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses

    • Yoshinao Ozaki
    • Hirotaka Imamaki
    • Norihiko Watanabe

    Short Communication Open access 03 October 2020 Pages: 693 - 699